Skip to main
AORT
AORT logo

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Artivion Inc. has demonstrated a significant operating margin improvement, reporting 17.8%, an increase of 770 basis points year over year, and exceeding prior estimates, indicating operational efficiency. The company anticipates further enhancement in gross margins, with projections for a 100 basis point increase in 2025 and an anticipated rise in adjusted EBITDA margin to 18.1%, reflecting ongoing strength in revenue generation. Additionally, the successful launch of AMDS is expected to contribute modestly to revenue growth, supported by robust gains in sales across key product lines such as On-X, aortic stent grafts, and BioGlue, bolstering a positive outlook for Artivion's financial performance.

Bears say

Artivion Inc. faces significant risks impacting its financial performance, including potential delays in clinical trials and new product approvals, which could lead to disappointing sales from new offerings and a weaker operating margin due to increased reinvestment. The company's recent quarterly results showed a decline in top-line revenue growth, dropping to 3.5% in Q4 2024 from 9.5% in Q3 2024, largely attributed to a cybersecurity incident that negatively affected sales by approximately $4.5 million. Furthermore, the bear case scenario indicates a concerning trend of revenue growth potentially slowing to the low- to mid-single digits, driven by underwhelming international expansion and new product launches.

Artivion (AORT) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Buy based on their latest research and market trends.

According to 8 analysts, Artivion (AORT) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.